skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Current and emerging treatments for the management of osteogenesis imperfecta

Review

(2511) Views  (1018) Full article downloads

Authors: Elena Monti, Monica Mottes, Paolo Fraschini, et al

Published Date August 2010 Volume 2010:6 Pages 367 - 381
DOI: http://dx.doi.org/10.2147/TCRM.S5932

Elena Monti1, Monica Mottes1, Paolo Fraschini2, PierCarlo Brunelli3, Antonella Forlino4, Giacomo Venturi1, Francesco Doro1, Silvia Perlini1, Paolo Cavarzere1, Franco Antoniazzi1
1Department of Life Sciences and Reproduction, Pediatric Clinic University of Verona, Verona, Italy; 2Istituto Di Ricovero e Cura a Carattere Scientifico, ‘E. Medea’, Associazione La Nostra Famiglia, Bosisio Parini (LC), Italy; 3Divisione di Ortopedia Pediatrica, Spedali Civili, Brescia, Italy; 4Department of Biochemistry “A. Castellani”, University of Pavia, Italy

Abstract: Osteogenesis imperfecta (OI) is the most common bone genetic disorder and it is characterized by bone brittleness and various degrees of growth disorder. Clinical severity varies widely; nowadays eight types are distinguished and two new forms have been recently described although not yet classified. The approach to such a variable and heterogeneous disease should be global and therefore multidisciplinary. For simplicity, the objectives of treatment can be reduced to three typical situations: the lethal perinatal form (type II), in which the problem is survival at birth; the severe and moderate forms (types III–IX), in which the objective is ‘autonomy’; and the mild form (type I), in which the aim is to reach ‘normal life’. Three types of treatment are available: non-surgical management (physical therapy, rehabilitation, bracing and splinting), surgical management (intramedullary rod positioning, spinal and basilar impression surgery) and medical-pharmacological management (drugs to increase the strength of bone and decrease the number of fractures as bisphosphonates or growth hormone, depending on the type of OI). Suggestions and guidelines for a therapeutic approach are indicated and updated with the most recent findings in OI diagnosis and treatment.
Keywords: osteogenesis imperfecta, bone genetic disorder, bone brittleness, “brittle bone disease”, connective tissue malfunction, short stature, progressive skeletal deformities, blue sclerae, dentinogenesis imperfecta, joint laxity, adult onset deafness







Readers of this article also read:

Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
Bone formation without lamina dura in the middle-aged and elderly: possible dependence on enamel
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
ABO and rhesus blood group distribution in Kurds
Molecular mechanisms and treatment strategies for Dupuytren’s disease
Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
Hyperhomocysteinemia decreases bone blood flow
If you don't take it – it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy